Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative trastuzumab ± everolimus (RAD001) in HER2-positive operable breast cancer
2007-004098-24Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Trastuzumab alone with Trastuzumab + everolimus (2 arms). Primary endpoint: Clinical tumor response rate by WHO criteria. Started Oct 2007; status: completed.
02
Drugs
everolimustrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-004098-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004098-24.